CNBC: "The Google for Investing Fintech"
Invest in the future with the future of investing. Search, discover, and invest in minutes – with Magnifi. No trade commissions.

No hidden execution charges.

Start investing today.
Learn more.
pixel

CLIN Insider Trading (Clinigen Group)

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): £12,080
Insider Selling (Last 12 Months): GBX 0

Clinigen Group Insider Trading History Chart

This chart shows the insider buying and selling history at Clinigen Group by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Clinigen Group Share Price & Price History

Current Price: GBX 638.50
Price Change: Price Increase of +3 (0.47%)
As of 09/24/2021 01:00 AM ET

This chart shows the closing price history over time for CLIN up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
CNBC: "The Google for Investing Fintech"
Invest in the future with the future of investing. Search, discover, and invest in minutes – with Magnifi. No trade commissions.

No hidden execution charges.

Start investing today.
Learn more.
pixel

Clinigen Group Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/27/2020Ian James NicholsonInsiderBuy2,000GBX 604£12,080
3/23/2020Shaun Edward ChiltonInsiderBuy10,000GBX 416£41,600
9/19/2019Nick KeherInsiderBuy3,900GBX 893£34,827
See Full Table
Insider Buying at Clinigen Group?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Clinigen Group and related companies.

SEC Filings (Institutional Ownership Changes) for Clinigen Group (LON:CLIN)

Clinigen Group logo
Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally. It operates through three segments: Commercial Medicines, Unlicensed Medicines, and Clinical Services. The Commercial Medicines segment acquires and licenses commercial medicines and then revitalises them, as well as provides access to licensed and branded generic medicines. The Unlicensed Medicines segment is involved in sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet medical need. The Clinical Services segment packages, supplies, distributes, and manages comparator medicines and services to clinical trials and investigator initiated trials. It offers Cardioxane that protects the heart against the cardiotoxic effects of anthracyclines; Ethyol, which protect against the harmful effects of chemotherapy medications and radiation treatment; Proleukin for the treatment of kidney cancer; Imukin that is used in chronic granulomatous disease; Totect, a dexrazoxane product; Foscavir, an anti-virals which work by stopping viruses from multiplying in number; AZEDR for the treatment of adult and pediatric patients; and Savene, which is indicated in adults for the treatment of anthracycline extravasation. The company was incorporated in 2008 and is headquartered in Burton-on-Trent, the United Kingdom.
Read More on Clinigen Group

Today's Range

Now: GBX 638.50
Low: 628.05
High: 640

50 Day Range

MA: GBX 629.07
Low: 586
High: 708.84

52 Week Range

Now: GBX 638.50
Low: 554
High: 891.79

Volume

1,340,368 shs

Average Volume

588,431 shs

Market Capitalization

£849.39 million

P/E Ratio

28.63

Dividend Yield

1.20%

Beta

N/A

Who are the company insiders with the largest holdings of Clinigen Group?

Clinigen Group's top insider shareholders include:
  1. Ian James Nicholson (Insider)
  2. Shaun Edward Chilton (Insider)
CNBC: "The Google for Investing Fintech"
Invest in the future with the future of investing. Search, discover, and invest in minutes – with Magnifi. No trade commissions.

No hidden execution charges.

Start investing today.
Learn more.
pixel